"Imagine the outrage from these companies if we announce the cure for Hep C and Aids, one shot cure...."
Plus Hep B which is a much bigger market and for which there is currently no cure. I think that were BLT to develop definite leads to cure Hep B then this would certainly accelerate Gilead's interest particularly if it were used in combination with a nucleoside antagonist.
In the meantime it will be interesting to see if Gilead bid for Arrowhead.
PDYOR.
BLT Price at posting:
$1.80 Sentiment: None Disclosure: Held